Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.

Journal of clinical pharmacology - 1 Feb 2012

O'Hara Gilles E, Philippon François, Gilbert Marcel, Champagne Jean, Michaud Véronique, Charbonneau Lyne, Pruneau Guylaine, Hamelin Bettina A, Geelen Peter, Turgeon Jacques

Abstract excerpt

Propafenone and its 5-hydroxy metabolite exhibit different electrophysiological properties. Objectives of the CAQ-PAF study were (1) to develop a strategy favoring propafenone instead of 5-hydroxypropafenone in plasma following oral administration of propafenone and (2) to evaluate the potential of low-dose quinidine to chronically inhibit CYP2D6. Patients (n = 102) with atrial fibrillation received propafenone...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents
Share to Atrial Fibrillation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Double-Blind Method

Share to Drug Therapy, Combination

Share to Heart Rate

Share to Quinidine

Source

Identifiers

PMID: 21508180
DOI: 10.1177/0091270011399574

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.PMID 21508180Read ↗

Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.Semantic proximity Read ↗

Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.Semantic proximity Read ↗

Relevance of CYP2D6 in the Efficacy and Toxicity of Flecainide in Patients With Atrial Fibrillation: A Cohort Study.Semantic proximity Read ↗

Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10.Semantic proximity Read ↗

Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.Semantic proximity Read ↗

The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.Semantic proximity Read ↗

Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects.Semantic proximity Read ↗

Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population.Semantic proximity Read ↗

The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.Semantic proximity Read ↗

Use of a propafenone metabolic ratio as a measure of CYP2D6 activity.Semantic proximity Read ↗

Steady-state plasma concentrations of propafenone--chirality and metabolism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.